Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.75.
Several equities research analysts have commented on BHC shares. Royal Bank of Canada increased their price objective on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a "sector perform" rating in a research note on Friday, November 1st. StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Friday, October 25th. Finally, Evercore ISI raised Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th.
Check Out Our Latest Analysis on BHC
A number of institutional investors have recently modified their holdings of BHC. Headlands Technologies LLC purchased a new position in Bausch Health Companies in the 2nd quarter valued at approximately $35,000. MQS Management LLC purchased a new position in shares of Bausch Health Companies in the second quarter valued at $71,000. Certuity LLC purchased a new position in shares of Bausch Health Companies in the second quarter valued at $75,000. Bfsg LLC raised its stake in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company's stock valued at $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management purchased a new stake in Bausch Health Companies during the 2nd quarter worth about $87,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.
NYSE BHC opened at $7.47 on Friday. The company has a fifty day simple moving average of $8.33 and a 200 day simple moving average of $7.28. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $11.46. The company has a market cap of $2.70 billion, a P/E ratio of -15.56 and a beta of 0.69.
Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm had revenue of $2.51 billion during the quarter, compared to analysts' expectations of $2.42 billion. During the same period last year, the company earned $1.03 earnings per share. The business's revenue was up 12.2% on a year-over-year basis. Sell-side analysts predict that Bausch Health Companies will post 3.74 EPS for the current year.
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.